Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
May 04, 2023 03:00 ET
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET
|
The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 26, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
RS BioTherapeutics Appoints Pharmaceutical and Consumer Products Veteran Curtis R. Rhine as Its Chief Financial Officer
April 17, 2023 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., April 17, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Appoints Pharmaceutical Industry Veteran Dean Hart as Chief Executive Officer
April 10, 2023 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
April 05, 2023 07:20 ET
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
IRBM Selected for Participation in National Chemical Biology Consortium
April 04, 2023 03:00 ET
|
IRBM
ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...
Global Cancer Vaccine Market to Generate USD 13.4 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
March 23, 2023 09:00 ET
|
Next Move Strategy Consulting
New York, March 23, 2023 (GLOBE NEWSWIRE) -- According to a report published by Next Move Strategy Consulting, the global Cancer Vaccine Market generated USD 5.75 billion in 2022 and is projected to...
AL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc.
March 20, 2023 06:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth...